Pharmacogenomics Journal

Papers
(The median citation count of Pharmacogenomics Journal is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study103
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data59
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform37
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study37
STRIPE partners in precision medicine series: provider perspective24
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study13
A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone13
Impact of population-specific pharmacogenomic variants on drug dosing in ICU patients12
Using ChatGPT to predict the future of personalized medicine12
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care12
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients11
Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population11
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder10
Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration10
Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants10
STRIPE partners in precision medicine series: Patient perspective10
Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients9
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing9
TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer9
The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?9
Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needs8
APF2: an improved ensemble method for pharmacogenomic variant effect prediction8
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine8
CYP2C19 point-of-care testing: where are we now and where should we go?8
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis8
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress7
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications7
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population7
Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients6
Potential of pharmacogenetics in treatment of chronic inflammatory diseases – a danish report overview from 2000 – 20246
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects6
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)6
Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China6
Genetic markers of early response to lurasidone in acute schizophrenia6
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance6
Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation6
Cost-effectiveness of genotype-guided acenocoumarol therapy in atrial fibrillation: a pharmacogenomic simulation study in the chilean population5
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci5
Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics5
Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy5
Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study5
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer5
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study5
An innovative model for pharmacogenomics critical results identification and intervention4
Influence of genetic biomarkers on cardiac diseases in childhood cancer survivors: a systematic review4
Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach4
STRIPE partners in precision medicine: regulatory perspective4
Association of pharmacodynamic genes with treatment outcomes in major depressive disorder: results from a Sardinian cohort4
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)4
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients4
Benchmarking large language models for replication of guideline-based PGx recommendations4
Genome-wide screening of pharmacogenomic biomarkers in jordanian patients with genetic disorders4
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study4
Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland3
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug3
Non-steroidal anti-inflammatory drug target gene associations with major depressive disorders: a Mendelian randomisation study integrating GWAS, eQTL and mQTL Data3
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone3
DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?3
CYPRI: a clinical decision-making tool to select psychiatric patients for pharmacogenetic testing3
Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study3
Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres3
Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services2
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?2
STRIPE partners in precision medicine series: pharmacist perspective2
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort2
The interplay between SLC6A4 and HTR1A genetic variants that may lead to antidepressant failure2
Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis2
Economic effectiveness of pharmacogenomics-guided prescribing for psychiatric disorders: a systematic review and meta-analysis2
Protein network and pathway analysis in a pharmacogenetic study of cyclosporine treatment response in Greek patients with psoriasis2
Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data2
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?2
Beyond the ‘Pregnancy Black Box’: a global roadmap for artificial intelligence-driven pharmacogenomics in maternal-neonatal health2
0.1251859664917